These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36211552)

  • 1. Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.
    Jacquinot Q; Meneveau N; Falcoz A; Bouhaddi M; Roux P; Degano B; Chatot M; Curtit E; Mansi L; Paillard MJ; Bazan F; Chaigneau L; Dobi E; Meynard G; Vernerey D; Pivot X; Mougin F
    Front Cardiovasc Med; 2022; 9():1000846. PubMed ID: 36211552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial.
    Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Capela A; Amarelo A; Marques C; Viamonte S; Alves A; Esteves D
    Eur J Prev Cardiol; 2023 Jul; 30(9):844-855. PubMed ID: 36857149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
    Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
    JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
    Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Preventive role of Regular Physical Training in Ventricular Remodeling, Serum Cardiac Markers, and Exercise Performance Changes in Breast Cancer in Women Undergoing Trastuzumab Therapy-An REH-HER Study.
    Hojan K; Procyk D; Horyńska-Kęstowicz D; Leporowska E; Litwiniuk M
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32392882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
    Bouwer NI; Steenbruggen TG; Rier HN; Kitzen JJEM; Smorenburg CH; van Bekkum ML; de Jong PC; Drooger JC; Holterhues C; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Int J Cancer; 2022 Aug; 151(4):616-622. PubMed ID: 35403708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
    Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Bouwer NI; Steenbruggen TG; van Rosmalen J; Rier HN; Kitzen JJEM; van Bekkum ML; Tije AJT; de Jong PC; Drooger JC; Holterhues C; Smorenburg CH; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Breast Cancer Res Treat; 2021 Apr; 186(3):851-862. PubMed ID: 33394273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    Guglin M; Munster P; Fink A; Krischer J
    Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy.
    Huang P; Huang JH; Zheng YB; Cao WM; Shao XY; Chen JQ; Huang Y; Li GL; Sharma K; Zhou HH; Wang XJ; Jin HC; Chen ZH
    Front Pharmacol; 2022; 13():883600. PubMed ID: 35991878
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    Kirkham AA; Paterson DI; Prado CM; Mackey JR; Courneya KS; Pituskin E; Thompson RB
    BMC Cancer; 2018 Sep; 18(1):864. PubMed ID: 30176834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.